Organisation paid for research Program year 2025 Source: CMS Open Payments

Digestive Disease Specialists

Neither a doctor nor a teaching hospital

Research payments

$831,305

144 payments

Through program year 2025, Digestive Disease Specialists is reported as receiving $831,305 in research payments, across 144 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$31,333	4
2024	Research	$44,600	9
2023	Research	$51,446	8
2022	Research	$23,927	5
2021	Research	$22,275	12
2020	Research	$425,866	59
2019	Research	$231,859	47

Breakdown

Who paid Research payments · program years 2019–2025

Ironwood Pharmaceuticals, Inc $253,663 18 payments
Celgene Corporation $225,094 18 payments
AbbVie, Inc. $177,303 63 payments
Shire North American Group Inc $88,928 33 payments
Braintree Laboratories, Inc. $36,279 2 payments
Takeda Pharmaceuticals U.S.A., Inc. $23,997 6 payments
E.R. Squibb & Sons, L.L.C. $18,749 1 payment
Pfizer Inc. $7,293 3 payments

Studies the money was for Research payments · program years 2019–2025

C3718-302 $242,667 13 payments
(RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) (RPC01-3101) $79,767 2 payments
Oral Budesonide Suspension Obs in Adolescents and Adult Subjects With Eosinophilic Esophagitis DB, Placebo-Controlled, RW $75,282 21 payments
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) $52,580 2 payments
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $36,279 2 payments
M15-991 $31,645 4 payments
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) (RPC01-3102) $29,341 1 payment
M16-000 $28,516 11 payments
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) - A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis $25,456 3 payments
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease $24,705 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.